Ahmedabad-based Intas Biopharmaceuticals (IBPL) has signed an agreement with Kotak Private Equity Group (KPEG) leading towards an investment of $10 million in IBPL as equity. Intas will utilise this investment for capital expansion to enhance its R&D & manufacturing capabilities based in Gujarat.According to an official release, the investment will boost Intas's efforts to launch new products internationally.The company is looking to double its R&D strength by the end of this year. After completion of its expansion, IBPL will be capable to undertake 10-12 new projects at a time, which will speed up the product development cycle. IBPL, which has already invested close to Rs 100 crore at its facility, plans to pump in additional Rs 150 crore over the next 4-5 years. IBPL is looking at developing innovative platform technologies in bio-therapeutics space, identify partnering opportunities, in-licensable IPs; and to build novel drug delivery systems, the release said.
